SOP Guide for Pharma

Sterile Injectable Manufacturing: SOP for Formulation Transfer from R&D to Manufacturing – V 2.0

Sterile Injectable Manufacturing: SOP for Formulation Transfer from R&D to Manufacturing – V 2.0

Standard Operating Procedure for Formulation Transfer from R&D to Manufacturing


Department Sterile Injectable Manufacturing
SOP No. SOP/SIM/131/2025
Supersedes SOP/SIM/131/2022
Page No. Page 1 of 15
Issue Date 24/06/2025
Effective Date 26/06/2025
Review Date 24/06/2026

1. Purpose

To define the procedure for effective and compliant transfer of injectable formulations from Research & Development (R&D) to Manufacturing, ensuring process consistency, safety, and regulatory compliance.

2. Scope

This SOP applies

to all sterile injectable products developed by R&D and intended for commercial scale-up or technology transfer into the Manufacturing department for production scale batches.

3. Responsibilities

  • R&D Team: Prepare and transfer all necessary technical documents and data.
  • Technology Transfer Team: Facilitate coordination between R&D and Manufacturing.
  • Manufacturing Team: Execute pilot, exhibit, and validation batches.
  • QA Team: Ensure all protocols, data, and change controls are in compliance.
  • QC Team: Perform required analysis and method transfer.

4. Accountability

The Head of Manufacturing is accountable for implementation of the formulation as per the transferred specifications and parameters.

5. Procedure

5.1 Initiation of Transfer

  1. R&D prepares a Technology Transfer Dossier (TTD) including:
    • Master Formula Record (MFR)
    • Bill of Materials
    • Critical Process Parameters (CPPs)
    • Quality Target Product Profile (QTPP)
    • Analytical method details
    • Container closure compatibility data

5.2 Transfer Planning

  1. Technology Transfer Team arranges a kick-off meeting involving:
    • R&D
    • Manufacturing
    • QA
    • QC
  2. Prepare a Transfer Plan and assign deliverables with timelines.

5.3 Pilot and Exhibit Batches

  1. Manufacturing executes batches under R&D supervision.
  2. R&D compares batch yield, pH, viscosity, particle load, and appearance with lab data.
  3. All deviations, observations, and challenges are documented (Annexure-1).

5.4 Validation Protocol

  1. Validation batches shall be manufactured using the transferred process and equipment.
  2. QA must approve the validation protocol and reports.
  3. All critical process parameters must remain within predefined limits.

5.5 Documentation Control

  1. Ensure controlled copies of:
    • Manufacturing Batch Records
    • Process Flow Diagrams
    • SOPs for new equipment/process
  2. Document training records for operators involved.

5.6 Risk Assessment

  1. Conduct a Failure Mode and Effects Analysis (FMEA) to identify:
    • Process risks
    • Material compatibility issues
    • Environmental factors affecting batch quality
  2. Implement mitigation strategies before commercial batch execution.

5.7 Post-Transfer Review

  1. QA shall conduct a post-transfer audit.
  2. Prepare a Technology Transfer Report summarizing:
    • Key challenges and resolutions
    • Validation summary
    • Final approved documents list

6. Abbreviations

  • TTD: Technology Transfer Dossier
  • MFR: Master Formula Record
  • QTPP: Quality Target Product Profile
  • CPP: Critical Process Parameter
  • FMEA: Failure Mode and Effects Analysis

7. Documents

  1. Technology Transfer Dossier – Annexure-1
  2. Batch Execution Report – Annexure-2
  3. Transfer Validation Checklist – Annexure-3

8. References

  • ICH Q8 – Pharmaceutical Development
  • ICH Q9 – Quality Risk Management
  • WHO Technical Report Series 961

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation Manufacturing Executive QA Executive Head QA
Department Production Quality Assurance Quality Assurance

11. Annexures

Annexure-1: Technology Transfer Dossier Summary

Document Status Remarks
Master Formula Record Submitted Approved by QA
Analytical Methods Submitted Validated
Process Flow Diagram Submitted Final Version

Annexure-2: Batch Execution Report

Batch No. Date Yield (%) Deviation Remarks
EX-003 12/06/2025 97.8 No Compliant

Annexure-3: Transfer Validation Checklist

Parameter Status Verified By
pH Range Within Limit Ravi Shah
Appearance Clear Solution Sunita Reddy
Sterility Passed QA Officer

Revision History

Revision Date Revision No. Details Reason Approved By
10/01/2022 1.0 Initial Issue New SOP QA Head
24/06/2025 2.0 Added risk management and validation checklist Annual Review QA Head
Exit mobile version